| Followers | 258 |
| Posts | 19732 |
| Boards Moderated | 0 |
| Alias Born | 10/03/2004 |
Monday, August 06, 2007 3:51:32 PM
However, not just anyone will be accepted for presentation in the breakout sections. That requires an abstract which must pass the selection committee.
I can't answer why the findings were not included in the PR. All I can say is that the fact that Diwan was selected to present to BRADA in a breakout session should indicate that previous results were confirmed in the latest round of testing. Although the forum is described as "open" the presentation may not be considered public enough since only qualified persons can attend:
"ATTENDEES:
The 2007 HHS BARDA Industry Day is an open meeting designed to provide a forum for representatives from relevant industries, academia, federal agencies and, international agencies who have an interest in working with the Federal Government in support of the HHS Pandemic Influenza Plan, the HHS PHEMCE Strategy and Implementation Plan, and Project BioShield."
I can't answer why the findings were not included in the PR. All I can say is that the fact that Diwan was selected to present to BRADA in a breakout session should indicate that previous results were confirmed in the latest round of testing. Although the forum is described as "open" the presentation may not be considered public enough since only qualified persons can attend:
"ATTENDEES:
The 2007 HHS BARDA Industry Day is an open meeting designed to provide a forum for representatives from relevant industries, academia, federal agencies and, international agencies who have an interest in working with the Federal Government in support of the HHS Pandemic Influenza Plan, the HHS PHEMCE Strategy and Implementation Plan, and Project BioShield."
Recent NNVC News
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM

